This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Osiris Therapeutics Inc (OSIR)

NASDAQ: Health Care

Company Income Statement
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Sales 24.31M 11.80M 42.40M 43.20M
Cost of Sales 6.07M 1.84M 531.00K 62.00K
Gross Operating Profit 18.24M 9.96M 41.87M 43.14M
Selling, General, and Administrative Expenses 15.53M 6.30M 7.88M 6.45M
Research & Development 4.95M 14.11M 19.16M 23.50M
Operating Income before D & A (EBITDA) -2.25M -10.44M 14.84M 13.19M
Depreciation & Amortization 587.00K 708.00K 745.00K 755.00K
Interest Income 0.00 0.00 0.00 0.00
Other Income - Net 414.00K 49.00K 100.00K 175.00K
Special Income / Charges 0.00 0.00 0.00 0.00
Total Income Before Interest Expenses (EBIT) -2.42M -11.10M 14.19M 12.61M
Interest Expense 0.00 0.00 0.00 0.00
Pre-Tax Income -2.42M -11.10M 14.19M 12.61M
Income Taxes -1.33M -37.00K 43.00K 241.00K
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations -1.09M -11.06M 14.89M 13.12M
Net Income From Discontinued Operations 42.73M 0.00 0.00 0.00
Net Income From Total Operations 41.64M -11.06M 14.89M 13.12M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income 41.64M -11.06M 14.89M 13.12M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-1.09M -11.06M 14.89M 13.12M
Preferred Dividends
Net Income Available To Common -1.09M -11.06M 14.89M 13.12M
Basic EPS from Continuing Ops. -0.04 -0.34 0.45 0.40
Basic EPS from Discontinued Ops. 1.29 0.00 0.00 0.00
Basic EPS from Total Operations 1.25 -0.34 0.45 0.40
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total 1.25 -0.34 0.45 0.40
Basic Normalized Net Income/Share -0.04 -0.34 0.45 0.40
EPS fr Continuing Ops. -0.04 -0.34 0.45 0.40
EPS fr Discontinued Ops 1.29 0.00 0.00 0.00
EPS fr Total Ops. 1.25 -0.34 0.45 0.40
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total 1.25 -0.34 0.45 0.40
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-0.04 -0.34 0.45 0.40
Dividends Paid per Share 0.00 0.00 0.00 0.00
OSIR News

OSIR Osiris Therapeutics Inc

Analysts Ratings for OSIR

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 1 1 1 1
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
GET OSIR ANALYST REPORT

Brokerage Partners

OSIR Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs